supp.fit

Lutein and Meso-Zeaxanthin: study protocols

16 study groups took Lutein together with Meso-Zeaxanthin. These are the doses the studies gave. They are not a recommendation.

Lutein: what the research found →

Dose per serving from research: Lutein

16 study groups in 10 studies say how much Lutein participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 5 mg to 10 mg, 63% of 16 study groups.

Daily doseStudy groups
2.5 mg to 5 mg
4
5 mg to 10 mg
10
10 mg to 25 mg
2

Dose per serving from research: Meso-Zeaxanthin

15 study groups in 10 studies say how much Meso-Zeaxanthin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 5 mg to 10 mg, 73% of 15 study groups.

Daily doseStudy groups
5 mg to 10 mg
11
10 mg to 25 mg
4

Commonly used together

16 of 16 study groups took Lutein and Meso-Zeaxanthin with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Zeaxanthin
16

16 study groups

Study
Supplemental Retinal Carotenoids Enhance Memory in Healthy Individuals with Low Levels of Macular Pigment in A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
2018 · active group · Healthy individuals with low macular pigment levels; mean age 45.42 years, 51.6% male
10 mg10 mg1 year45
Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial
2022 · active group · Cognitively healthy adults aged 65 years and older
10 mg10 mg2 years30
Visual Function and Macular Carotenoid Changes in Eyes with Retinal Drusen-An Open Label Randomized Controlled Trial to Compare a Micronized Lipid-Based Carotenoid Liquid Supplementation and AREDS-2 Formula
2020 · LM group · Adults aged 54–80 with retinal drusen and risk of age-related macular degeneration
15 mg10 mg26 weeks29
Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment
2012 · Group 2 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated
10 mg10 mg8 weeks10
Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment
2012 · Group 3 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated
3 mg17 mg8 weeks10
Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration
2013 · Group 2 · Adults with or without age-related macular degeneration; age and sex not reported
10 mg10 mg8 weeks—
Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration
2013 · Group 3 · Adults with or without age-related macular degeneration; age and sex not reported
3 mg17 mg8 weeks—
Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease
2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported
10 mg10 mg1 year50
Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration
2014 · Group 2 · People with early age-related macular degeneration; age and sex not stated
10 mg10 mg1 year21
Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration
2014 · Group 3 · People with early age-related macular degeneration; age and sex not stated
3 mg17 mg1 year14
The impact of macular pigment augmentation on visual performance using different carotenoid formulations
2012 · group 2 · Adults, 19–64 years (mean age 51 years), 19 male and 17 female across the study; condition not specified
10 mg10 mg26 weeks—
The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial
2015 · Macushield, Alzheimer's disease patients · Adults with Alzheimer's disease; age range and sex not stated
10 mg10 mg26 weeks—
The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial
2015 · Macushield, age-similar control subjects · Age-similar control subjects; age range and sex not stated
10 mg10 mg26 weeks—
Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration
2015 · Group 1 · People with early age-related macular degeneration; age and sex not specified
20 mg—3 years—
Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration
2015 · Group 2 · People with early age-related macular degeneration; age and sex not specified
10 mg10 mg3 years—
Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration
2015 · Group 3 · People with early age-related macular degeneration; age and sex not specified
3 mg17 mg3 years—
Lutein and Meso-Zeaxanthin: study protocols | supp.fit